Detalhe da pesquisa
1.
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Future Oncol
; 20(14): 891-901, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38189180
2.
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(1): 30-41, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335217
3.
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(2): 400, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36697966
4.
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 33(5): 1100-7, 2015 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26334219
5.
Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia.
Leuk Lymphoma
; 61(8): 1965-1973, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32432489
6.
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Target Oncol
; 12(6): 775-785, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29067643
7.
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Clin Cancer Res
; 21(8): 1888-95, 2015 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25652454
8.
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
J Clin Oncol
; 30(13): 1527-33, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22454420
9.
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
Eur J Cancer
; 47(15): 2256-64, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21852114
10.
Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.
J Clin Oncol
; 27(31): 5262-9, 2009 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19738123